Fatty-Acid Acylation And The Albumin-Binding Design

The chemistry is an amide bond. A lysine side-chain amine is acylated with an activated fatty acid, and in current designs the acid is not attached directly but through a spacer: one gamma-linked glutamate residue, then one or two units of 8-amino-3,6-dioxaoctanoic acid, a short ethylene glycol fragment usually abbreviated AEEA or OEG. The spacer holds the lipid away from the peptide backbone and adds a negative charge and some hydrophilicity to offset the chain.

The acid itself is either a mono-acid, such as hexadecanoic acid, or a diacid with a free carboxylate at the far end, such as octadecanedioic or eicosanedioic acid. A diacid design leaves an ionisable group at the tail of the lipid, which alters both albumin affinity and aqueous solubility relative to a plain fatty chain.

Sequence modifications commonly travel with the acylation. Substituting an alpha-aminoisobutyric acid residue near the N-terminus, or replacing a lysine elsewhere with arginine so that acylation has only one possible site, are both design choices made to control where the chain goes and what enzymes can reach.

What the modification adds to the molecular weight

Each fragment contributes a fixed mass once the amide bonds have formed and water has been lost. The figures below are average masses computed from standard atomic weights for the acyl or residue fragment as incorporated, not for the free acid.

A C18 diacid with one gamma-glutamate and two AEEA units therefore adds roughly 715.9 g/mol to the unmodified sequence, which is a substantial fraction of a thirty-residue peptide. Whether that total is quoted as an average or a monoisotopic figure matters at this size, because the two diverge by several mass units once the molecule passes 4,000 g/mol.

Known acylation designs in the literature

The progression from a C16 mono-acid on a bare glutamate spacer to a C20 diacid on an extended spacer is the visible history of the design being tuned. Longer chains and terminal carboxylates raise albumin affinity; longer spacers keep the peptide's own binding surface clear of the lipid.

The failure mode: hydrophobicity that outruns the method

A C20 diacid is a large hydrophobic addition to a water-soluble molecule, and the material behaves accordingly. Lipidated peptides self-associate in aqueous solution, forming micelle-like aggregates above a concentration that depends on chain length, pH and ionic strength. They also adsorb to hydrophobic surfaces, including polypropylene labware and stainless tubing.

On a reverse-phase separation it shows up as late elution, broad or split peaks, and a main peak whose shape changes with sample concentration. A peak that sharpens when the sample is diluted, or that narrows when the organic content of the sample solvent is raised, is reporting aggregation rather than an impurity. Chromatographic conditions developed for an unmodified peptide will rarely transfer to its acylated analogue without a steeper or longer gradient.

The second and less visible problem is positional isomerism. A sequence with more than one free lysine can be acylated at the wrong one. That product has the identical elemental composition and the identical mass as the intended one, so a mass identity check cannot separate them. Only a chromatographic separation that resolves the two, or a fragmentation experiment that localises the modification, will.

Where the published record stops

Material listed by Aurum is independently assayed for purity by reverse-phase HPLC, and identity is assayed by mass spectrometry. For an acylated peptide there is a specific limit in that combination worth stating plainly: a mass identity result confirms that the acyl group and spacer are present at the expected total mass, and it does not establish which lysine carries them, because positional isomers are isobaric.

Albumin binding affinity, aggregation threshold and critical micelle concentration are properties of this class of molecule that are measured in the literature by surface plasmon resonance, isothermal titration calorimetry and fluorescent probe methods. None of them is among the specifications Aurum publishes. Published purity is HPLC purity and is not net peptide content, which is also not published.

Common questions

Is a lipidated peptide still a peptide?

Structurally it is a peptide carrying a non-peptidic side-chain modification. It is synthesised by the same solid-phase chemistry, with the acylation performed on a selectively protected lysine, and it is analysed by the same methods with adjusted conditions.

Why a diacid rather than a plain fatty acid?

The free terminal carboxylate is ionised at neutral pH, which keeps the molecule more soluble than an equivalent-length mono-acid would and changes how the chain sits in the albumin binding site. It is a solubility and affinity trade rather than a length change alone.

Does the spacer do anything, or is it filler?

It sets the distance between the lipid and the peptide surface. Designs with the acid attached directly to lysine exist, and they generally show weaker retention of the peptide's own structural properties, which is the reason the spacer was introduced.

Why does an acylated peptide elute so much later?

Reverse-phase retention tracks hydrophobicity, and a C18 or C20 chain is one of the most hydrophobic fragments that can be attached to a peptide. Retention shifts of many minutes relative to the unmodified sequence under the same gradient are ordinary.